Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY

Vaxart is urging shareholders to vote for all six of its director nominees on the WHITE proxy card ahead of its July 16, 2026 Annual Meeting. The company highlights strategic progress on its oral vaccine pipeline, including Phase 2b COVID-19 trials and partnerships with Dynavax, while defending its board against dissident nominees it claims lack relevant biotech expertise. Vaxart has made multiple settlement offers to resolve the proxy contest.